Receive E-mail Alerts

This portion of our website contains archival information. Archived information should be considered accurate only as of the date listed next to the event. Archived information may be superseded by more recent information we have disclosed in later presentations, press releases, filings with the Securities and Exchange Commission or otherwise. Archived information may contain forward-looking statements. Actual results may materially differ based on several factors, including those described in the archived information, press releases and our filings with the SEC.

Date Title   02/11/10 Targacept Reports Fourth Quarter and 2009 Financial Results 02/08/10 Targacept Awarded a Grant from The Michael J. Fox Foundation to Conduct Biomarker Research for Parkinson's Disease 02/04/10 Targacept to Report Fourth Quarter and 2009 Financial Results on February 11, 2010 02/02/10 Targacept to Present at BIO CEO & Investor Conference 01/11/10 Targacept Receives $200 Million Upfront Payment from AstraZeneca 12/10/09 Targacept Initiates Phase 2 Study of TC-5619 in Cognitive Dysfunction in Schizophrenia 12/03/09 Targacept to Host Conference Call Today at 10:00 AM to discuss AstraZeneca Collaboration on TC-5214 for Major Depressive Disorder 12/03/09 AstraZeneca and Targacept Form Global Collaboration and License Agreement for Late-stage Investigational Product TC-5214 for the Treatment of Major Depressive Disorder 11/16/09 Targacept Added to NASDAQ Biotechnology Index 11/11/09 Targacept to Present at the Lazard Capital Markets 6th Annual Healthcare Conference 11/05/09 Targacept Reports Third Quarter 2009 Financial Results 10/29/09 Targacept to Report Third Quarter Financial Results on November 5, 2009 10/21/09 Targacept Announces Participation in Upcoming Conferences 10/15/09 Targacept Presents Data from Highly Successful Phase 2b Trial of TC-5214 as Augmentation Treatment for Major Depressive Disorder 10/08/09 Targacept Announces Pricing of Common Stock Offering 10/08/09 Targacept Announces Common Stock Offering 09/10/09 Data to be Presented on Multiple Targacept NNR Therapeutics at Society for Neuroscience Satellite Symposium 08/05/09 Targacept Reports Second Quarter 2009 Financial Results 07/29/09 Targacept to Report Second Quarter Financial Results on August 5, 2009 07/23/09 Targacept Awarded Grant from Michael J. Fox Foundation to Conduct Research in the Treatment of Side Effects of Parkinson's Disease Therapy 07/15/09 Targacept's TC-5214 Achieves All Primary and Secondary Outcome Measures in Phase 2b Trial as Augmentation Treatment for Major Depressive Disorder 07/08/09 Targacept Announces Decision by AstraZeneca to Advance AZD3480 Program in ADHD 05/11/09 Targacept Reports First Quarter 2009 Financial Results 05/11/09 Targacept Announces Positive Top-Line Results From Phase II Study of AZD3480 in Adult ADHD 05/04/09 Targacept to Report First Quarter Financial Results on May 11, 2009 04/23/09 Targacept Initiates Phase 2 Study of TC-5214 in Patients with Resistant Hypertension 03/11/09 Targacept Provides Update on TC-6499 and Pain Program in GlaxoSmithKline Alliance